SUBSCRIBE
SUBSCRIBE

Fibrobiologics

IN THE PRESS
Press Releases
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 26, 2026
 · 
6 min read
Press Releases
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
June 22, 2026
 · 
5 min read
Press Releases
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
June 16, 2026
 · 
5 min read
Press Releases
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
June 3, 2026
 · 
5 min read
Press Releases
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
May 24, 2026
 · 
5 min read
Press Releases
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 18, 2026
 · 
5 min read
Press Releases
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
May 11, 2026
 · 
6 min read
Press Releases
FibroBiologics CEO Issues Letter to Shareholders - May 5, 2026
May 5, 2026
 · 
6 min read
Press Releases
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 4, 2026
 · 
6 min read
Press Releases
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 4, 2026
 · 
4 min read
Load More
JOBS